Pityriasis rosea during etanercept therapy.

Eur Rev Med Pharmacol Sci

Department of Social Territorial Medicine, Section of Dermatology, University of Messina, Italy.

Published: January 2010

Multiple bioengineered agents has been recently developed to attack other parts of the immune/inflammatory system, achieving therapeutic implications for dermatologic diseases. On the other side, each new therapy has the potential for adverse cutaneous reactions. We present herein the first two cases of Gibert's pityriasis rosea occurring during etanercept therapy and discuss possible links between this common, etiologically still unexplained exanthema and anti-tumor necrosis factor-alpha drugs.

Download full-text PDF

Source

Publication Analysis

Top Keywords

pityriasis rosea
8
etanercept therapy
8
rosea etanercept
4
therapy multiple
4
multiple bioengineered
4
bioengineered agents
4
agents developed
4
developed attack
4
attack parts
4
parts immune/inflammatory
4

Similar Publications

Pityriasis rosea (PR) is a self-limited exanthem associated with the endogenous systemic reactivation of human herpesvirus (HHV)-6 and HHV-7. The disease typically begins with a single erythematous patch on the trunk (herald patch), followed by a secondary eruption of smaller papulosquamous lesions. Rarely, the herald patch may be the only cutaneous manifestation of PR.

View Article and Find Full Text PDF

The risks of pityriasis rosea in pregnancy: a review.

Int J Womens Dermatol

March 2025

The Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York City, New York.

Objective: This review aims to consolidate available evidence, identify research gaps, and advocate for a more informed approach to the management of pityriasis rosea in pregnant individuals.

Data Sources: PubMed, Web of Science, and Directory of Open Access Journals were systematically searched based on the keywords "pityriasis rosea," "pityriasis circinate," "roseola annulate," "herpes tonsurans maculosus," "herald patch," and "pregnancy" on January 25, 2024 for publications between 1950 to 2024.

Study Selection: Studies containing outcomes data for pregnant patients with established PR were included.

View Article and Find Full Text PDF

A retrospective analysis of medications associated with pityriasis rosea reported in the FDA adverse events reporting system.

Arch Dermatol Res

January 2025

Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, 1150 NW 14th Street, Miami, FL, 33136, USA.

Pityriasis rosea (PR) is an acute exanthematous disease with an uncertain physiopathology, increasingly recognized as potentially drug induced. This study aims to investigate medication triggers associated with PR by analyzing cases reported in the FDA Adverse Event Reporting System (FAERS) database. A retrospective review of 343 PR cases reported in the FAERS database from January 1, 1998, to March 31, 2024, was conducted.

View Article and Find Full Text PDF

Beyond the Herald Patch: Exploring the Complex Landscape of Pityriasis Rosea.

Am J Clin Dermatol

January 2025

Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL, 33136, USA.

Pityriasis rosea (PR) is a prevalent dermatological condition characterized by a distinctive herald patch, followed by secondary eruptions, often forming a "Christmas tree" pattern on the trunk. Despite its recognizable clinical presentation, the etiology of PR remains uncertain, with hypotheses pointing to both infectious and noninfectious origins. Human herpesviruses (HHV) 6 and 7 have been implicated, with evidence suggesting viral reactivation as a potential trigger.

View Article and Find Full Text PDF

Pityriasis rosea is a self-limiting skin disorder that can occur in pediatric patients. We report an atypical presentation of a 23-month-old male with a generalized rash similar in appearance to pityriasis rosea. We then review the literature on pityriasis rosea and its application to pediatrics.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!